Delivery Order SPE2DB25D3018-SPE2DB25FUYCW
Award Date 7/31/25
Potential Completion Date 8/1/25
Potential Value $4.2K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a $120,474.64 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes. This competitively awarded, firm fixed-price contract with no set-aside designation is scheduled for completion by July 25, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adult immunization, representing part of the Defense...
- The Defense Logistics Agency awarded a delivery order valued at $2,106.20 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed price delivery order was competitively awarded without set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adults aged 18 and older, and this...
- The Defense Logistics Agency awarded a delivery order valued at $4,623.24 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on July 23, 2025, with an ultimate completion date of July 24, 2025. HEPLISAV-B is a hepatitis B vaccine indicated for adult immunization. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child...
- The Defense Logistics Agency awarded a $4,212.40 delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes with an ultimate completion date of July 22, 2025. HEPLISAV-B is a recombinant hepatitis B vaccine administered via intramuscular injection, representing a critical pharmaceutical product for military medical readiness and healthcare operations. This is a firm fixed-price, non-set-aside contract with performance in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $2,527.44 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 mcg/0.5 mL syringes on July 31, 2025, with completion scheduled for August 1, 2025. HEPLISAV-B is a recombinant hepatitis B vaccine used for immunization of adults. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes valued at $4,279.18. This is a firm fixed price delivery order with an ultimate completion date of July 22, 2025, and represents a non-set-aside competitive award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adult...
- The Defense Logistics Agency awarded a delivery order valued at $2,527.44 to AmerisourceBergen Drug Corp for HEPLISAV-B vaccine (20 mcg/0.5 mL syringe) on July 21, 2025, with completion scheduled for July 22, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. The place of performance is AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $15,164.64 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on July 22, 2025, with an ultimate completion date of July 23, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical federal medical procurement vendor, particularly...
- The U.S. Department of Defense's Medical Supply Chain awarded a $9,236.60 delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of HEPLISAV-B 20 mcg/0.5 mL syringes. This competitively awarded, firm fixed-price contract represents a single delivery order fulfillment without set-aside provisions. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of July 23, 2025. This delivery order is a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B hepatitis B vaccine (20 mcg/0.5 mL syringe) with a ceiling value of $2,563.43. The order was competitively awarded without set-aside restrictions and is set for completion by August 1, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through...